Active, Not Recruiting
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326
- Conditions
- Hypopigmentation, Pigmentation Disorders, Skin Diseases, +2 more
- Locations
-
- California Dermatology & Clinical Research Institute Encinitas, California, United States
- Marvel Clinical Research Huntington Beach, California, United States
- Wallace Medical Group, Inc Los Angeles, California, United States
- Encore Medical Research of Boynton Beach Boynton Beach, Florida, United States